Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1/2 1Phase 1 1

Status

Recruiting 5Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 5Sarcoma 1

Conditions

Uveal Melanoma 4Melanoma 2Sarcoma, Clear Cell 1Sarcoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 512Specimen Handling 381Carboplatin 371Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 302Cyclophosphamide 295Radiotherapy 254Paclitaxel 252Biopsy 235Gemcitabine 229Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 154Rituximab 151Fluorouracil 148venetoclax 142atezolizumab 141Docetaxel 141Drug Therapy 140Etoposide 138Doxorubicin 131Ipilimumab 125Radiosurgery 118Lenalidomide 117Prednisone 116Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × tebentafusp × 1 year × Clear all
NCT07276386 2026-03-31

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
18 enrolled
Dermatologic

Uveal Melanoma

NCT07057596 2026-03-06

NEO-TB

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting
19 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT06070012 2026-02-27

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

University of Pittsburgh

Phase 2 Recruiting
44 enrolled
Dermatologic

Uveal Melanoma

NCT06627244 2026-02-23

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

University of Miami

Phase 2 Recruiting
30 enrolled
Dermatologic

Uveal Melanoma

NCT06942442 2025-12-26

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Sarcoma Alliance for Research through Collaboration

Phase 2 Recruiting
47 enrolled
Sarcoma

Sarcoma, Sarcoma, Clear Cell

NCT05315258 2025-07-17

TebeMRD

University of Oxford

Phase 2 Active not recruiting
850 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡